Molecular Formula | C14H11F3N2OS |
Molar Mass | 312.31 |
Density | 1.5 |
Boling Point | 429.3±55.0 °C(Predicted) |
Flash Point | 213.4℃ |
Appearance | Shape powder, color white to beige |
pKa | 0.23±0.20(Predicted) |
Storage Condition | room temp |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
Physical and Chemical Properties | Bioactive XAV-939 (NVP-XAV939) selectively inhibits Wnt/β-catenin-mediated transcription by inhibiting tankyrase1/2. IC50 is 11 nM/4 nM in cell-free test, which regulates axin level, but has no effect on CRE, NF-κB and TGF-β. |
Use | Uses a tankyrase (TNKS) inhibitor that antagonizes Wnt signaling via stimulation of β-catenin degradation and stabilization of axin. XAV 939 inhibits proliferation of the Wei-catenin-dependent colon carcinom a cell line DLD-1. |
Hazard Symbols | T - Toxic |
Risk Codes | R25 - Toxic if swallowed R36 - Irritating to the eyes |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S26/45 - |
UN IDs | UN 2811 |
WGK Germany | 3 |
HS Code | 29349990 |
Hazard Class | 6.1 |
Packing Group | III |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.202 ml | 16.01 ml | 32.019 ml |
5 mM | 0.64 ml | 3.202 ml | 6.404 ml |
10 mM | 0.32 ml | 1.601 ml | 3.202 ml |
5 mM | 0.064 ml | 0.32 ml | 0.64 ml |
Target
Target Value
TNKS2
(Cell-free assay) 4 nM
TNKS1
(Cell-free assay) 11 nM
in vitro studies
XAV939 is a small molecule selective inhibitor that inhibits transcription regulated by the Wnt pathway transcription factor β-catenin. The IC50 is 11 and 4nM when it acts on TNKS1 and TNKS2, respectively. XAV939 promotes the degradation of β-catenin by stabilizing the limit concentration composition of axin and the broken mixture, while stabilizing axin is by blocking the PAR enzyme: end anchor polymerase 1 and 2. The two end-anchor polymerase subtypes interact because of the highly conserved region of axin, which promotes the degradation of end-anchor polymerase through the ubiquitin-proteasome pathway. XAV939 inhibits Wnt/β-catenin pathway activity has been used in a variety of cancer treatments. XAV939 particularly inhibits end-anchor polymerase PARP activity. XAV939 significantly reduces the level of DNA-PKcs protein, indicating the key to end anchor polymerase PARP activity when maintaining the stability of DNA-PKcs protein. When treated with 1.0 μM XAV939 for 12 hours, the DNA-PKcs protein level was reduced to the lowest level. Compared with the control group treated with DMSO, the relative expression level was less than 25%. Treatment of human lymphocytes with 1.0 μM XAV939 resulted in a marked rise in end-anchor polymerase 1 levels.
In vivo studies
XAV-939 (3 mL, 10 nM) has a suppressive effect on elevated MMP-13 levels in the rat OA model. XAV-939 (1 mg/mL, I .p.) ameliorates the psoriasiform skin disease induced by IMQ. XAV-939 results in a significant decrease in the IMQ-induced epidermal hyperplasia (indicated by acanthosis) and dermal inflammatory infiltrates in mice.